Teva Pharmaceutical Statistics
Total Valuation
Teva Pharmaceutical has a market cap or net worth of $17.92 billion. The enterprise value is $32.80 billion.
Important Dates
The next confirmed earnings date is Wednesday, May 7, 2025, before market open.
| Earnings Date | May 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Teva Pharmaceutical has 1.15 billion shares outstanding. The number of shares has increased by 1.07% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.15B |
| Shares Change (YoY) | +1.07% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.44% |
| Owned by Institutions (%) | 73.65% |
| Float | 1.14B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 6.10 |
| PS Ratio | 1.07 |
| Forward PS | 1.02 |
| PB Ratio | 3.30 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 23.92 |
| P/OCF Ratio | 14.37 |
| PEG Ratio | 1.44 |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 7.40, with an EV/FCF ratio of 43.79.
| EV / Earnings | n/a |
| EV / Sales | 1.98 |
| EV / EBITDA | 7.40 |
| EV / EBIT | 9.73 |
| EV / FCF | 43.79 |
Financial Position
The company has a current ratio of 0.98, with a Debt / Equity ratio of 3.18.
| Current Ratio | 0.98 |
| Quick Ratio | 0.50 |
| Debt / Equity | 3.18 |
| Debt / EBITDA | 3.98 |
| Debt / FCF | 24.28 |
| Interest Coverage | 3.37 |
Financial Efficiency
Return on equity (ROE) is -28.30% and return on invested capital (ROIC) is 8.06%.
| Return on Equity (ROE) | -28.30% |
| Return on Assets (ROA) | 5.09% |
| Return on Invested Capital (ROIC) | 8.06% |
| Return on Capital Employed (ROCE) | 12.71% |
| Revenue Per Employee | $449,199 |
| Profits Per Employee | -$44,502 |
| Employee Count | 36,830 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 2.41 |
Taxes
In the past 12 months, Teva Pharmaceutical has paid $676.00 million in taxes.
| Income Tax | 676.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +11.28% in the last 52 weeks. The beta is 0.62, so Teva Pharmaceutical's price volatility has been lower than the market average.
| Beta (5Y) | 0.62 |
| 52-Week Price Change | +11.28% |
| 50-Day Moving Average | 15.30 |
| 200-Day Moving Average | 17.52 |
| Relative Strength Index (RSI) | 59.66 |
| Average Volume (20 Days) | 12,300,761 |
Short Selling Information
| Short Interest | 30.34M |
| Short Previous Month | 34.80M |
| Short % of Shares Out | 2.66% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.56 |
Income Statement
In the last 12 months, Teva Pharmaceutical had revenue of $16.54 billion and -$1.64 billion in losses. Loss per share was -$1.45.
| Revenue | 16.54B |
| Gross Profit | 8.06B |
| Operating Income | 3.37B |
| Pretax Income | 131.00M |
| Net Income | -1.64B |
| EBITDA | 4.43B |
| EBIT | 3.37B |
| Loss Per Share | -$1.45 |
Full Income StatementBalance Sheet
The company has $3.30 billion in cash and $18.18 billion in debt, giving a net cash position of -$14.88 billion or -$12.98 per share.
| Cash & Cash Equivalents | 3.30B |
| Total Debt | 18.18B |
| Net Cash | -14.88B |
| Net Cash Per Share | -$12.98 |
| Equity (Book Value) | 5.72B |
| Book Value Per Share | 4.74 |
| Working Capital | -244.00M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $1.25 billion and capital expenditures -$498.00 million, giving a free cash flow of $749.00 million.
| Operating Cash Flow | 1.25B |
| Capital Expenditures | -498.00M |
| Free Cash Flow | 749.00M |
| FCF Per Share | $0.65 |
Full Cash Flow StatementMargins
Gross margin is 48.74%, with operating and profit margins of 20.38% and -9.91%.
| Gross Margin | 48.74% |
| Operating Margin | 20.38% |
| Pretax Margin | -7.76% |
| Profit Margin | -9.91% |
| EBITDA Margin | 26.78% |
| EBIT Margin | 20.38% |
| FCF Margin | 4.53% |
Dividends & Yields
Teva Pharmaceutical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.07% |
| Shareholder Yield | -1.07% |
| Earnings Yield | -9.15% |
| FCF Yield | 4.18% |
Dividend DetailsAnalyst Forecast
The average price target for Teva Pharmaceutical is $24.00, which is 53.50% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $24.00 |
| Price Target Difference | 53.50% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on July 1, 2004. It was a forward split with a ratio of 2:1.
| Last Split Date | Jul 1, 2004 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Teva Pharmaceutical has an Altman Z-Score of 0.48 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.48 |
| Piotroski F-Score | 6 |